According to the Spinal Cord Injury Information Network, in the U.S. around 200,000 people are living with spinal cord injury and half of all spinal cord injuries occur among young people in the age group of between 16 years and 30 years. The major causes observed in acute spinal cord injury are birth injuries, falls, diving accidents, motorcycle accidents, trampoline accidents, sports injuries, and spinal cord infections. Here is a company in the frontline RespireRx Pharmaceuticals Inc. (OTCQB: RSPI)
The major symptoms observed in acute spinal cord injuries are muscle weakness, loss of voluntary muscle movement, breathing problems, loss of sensation in body parts and loss of bowel and bladder function. Other than accidental injuries the major diseases such as cervical myelopathy, scoliosis, kyphosis, myelopathy, spondylolisthesis, sciatica are also responsible for causing acute spinal cord injuries.
The FDA has fast tracked development of AbbVie’s potential spinal injury drug, elezanumab, a process that will be aided by digital analysis.
The regulator has also granted it orphan status, which cuts development costs and potentially boosts profits if approved.
Elezanumab is a monoclonal antibody that binds selectively to repulsive guidance molecule, which is known to inhibit regeneration of neurons and functional recovery following central nervous system damage.
The drug is being investigated to treat spinal cord injuries, multiple sclerosis and acute ischemic stroke, and is in phase 2 development in spinal cord injury.
AbbVie is partnering with the Shirley Ryan AbilityLab, a specialist in rehabilitation medicine, and MC10, a health digital solutions company, in a pilot study involving 20 spinal cord injury patients.
MC10 combines sensors with clinical analytics, which it uses to gain insights from physiological data that it collects.
The pilot study is due to be completed in around two months.
AbbVie is also partnering with United Spinal Association and the North American Spinal Cord Injury Consortium to support spinal cord injury awareness and incorporate insights from the patient community into its clinical research and outreach.
The company is targeting cervical spinal cord injuries, which are the most common and debilitating forms of injury with many occurring in younger people, typically male adults.
RespireRx Pharmaceuticals Inc. (OTCQB: RSPI), a leader in the discovery and development of innovative and revolutionary treatments to combat diseases caused by disruption of neuronal signaling, recently announced the publication by Dr. David Fuller and his colleagues of a review article entitled “Ampakines Stimulate Phrenic Motor Output after Cervical Spinal Cord Injury” in a special issue of the peer-reviewed journal, Experimental Neurology (https://authors.elsevier.com/a/1boWx_L5Mw1dO). In studies funded by grants from the National Institutes of Health, Dr. Fuller, a long-time RespireRx collaborator, describes the ability of CX717, one of the Company’s lead ampakines, to improve motor nerve function in an animal model of spinal cord injury. CX717 improved the electrical activity of the phrenic motor nerve when recorded below the site of the spinal injury, an effect which increased over the course of 8 weeks.
According to Dr. Fuller, “Autonomic and cardiovascular dysfunctions are of paramount concern in persons with spinal cord injury. In our preclinical studies, we have measured the activity of the phrenic motor nerve, which activates breathing by stimulating the diaphragm. Our data shows that ampakines very effectively stimulate neural drive to the diaphragm after spinal cord injury. Ampakines may, therefore, be of use in the treatment of spinally damaged patients, particularly during rehabilitation.”
Arnold Lippa, Ph.D., Chief Scientific Officer and Executive Chairman of the Board of Directors said, “Our ongoing ampakine collaboration with Dr. Fuller is a part our overall neuromodulator program to discover and develop novel drugs for the treatment of psychiatric and neurological disorders. The research results from Dr. Fuller’s laboratory add considerable support for our intention to translationally extend this work to human clinical trials.”
RespireRx Pharmaceuticals Inc. (OTCQB: RSPI) closed up over 20% yesterday and could be bouncing back to levels not seen in months. The stock has gained over 90% this month. The price continues to press higher, climbing toward the significant resistance zone 0.0080-0.0090, if it close above 0.01 in the next few weeks, we believe that it will open the door to 0.02 .